Drugs / Clofarabine
last change Jul 2026 re-read 2 minutes ago

Clofarabine

Other / unclassified

Developed for
acute myeloid leukemia · myelodysplastic syndrome · leukemia · acute lymphoblastic leukemia · chronic myeloid leukemia · chronic myelomonocytic leukemia · Hodgkins lymphoma · acute myeloid leukemia with 11q23 abnormalities
+73 more · acute myeloid leukemia with t(8;21)(q22;q22) translocation · chronic lymphocytic leukemia/small lymphocytic lymphoma · lymphoma · plasma cell myeloma · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · Burkitt lymphoma · non-Hodgkin lymphoma · acute promyelocytic leukemia · adult acute lymphoblastic leukemia · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · Langerhans cell histiocytosis · lymphoblastic lymphoma · acute biphenotypic leukemia · acute leukemia · B-cell chronic lymphocytic leukemia · cancer · diffuse large B-cell lymphoma · hematopoietic and lymphoid cell neoplasm · juvenile myelomonocytic leukemia · myeloproliferative neoplasm · urothelial carcinoma · acute erythroid leukemia · acute leukemia of ambiguous lineage · acute megakaryoblastic leukemia in adult · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia with multilineage dysplasia · acute myeloid leukemia, del(5q31-q32) · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myelomonocytic leukemia M4 · acute undifferentiated leukemia · adult acute monocytic leukemia · anaplastic large cell lymphoma · anemia · angioimmunoblastic T-cell lymphoma · aplastic anemia · atypical chronic myeloid leukemia, BCR-ABL1 negative · B-cell acute lymphoblastic leukemia · B-cell neoplasm · B-cell non-Hodgkin lymphoma · bilineal acute myeloid leukemia · bone marrow failure syndrome · childhood leukemia · follicular lymphoma · hematopoietic and lymphoid system neoplasm · high grade B-cell lymphoma · high-grade B-cell lymphoma double-hit/triple-hit · immune dysregulation, autoimmunity, and autoinflammation · immunodeficiency disease · lymphoplasmacytic lymphoma · lymphoproliferative syndrome · mantle cell lymphoma · marginal zone lymphoma · metabolic disease · mixed phenotype acute leukemia, B/myeloid · mixed phenotype acute leukemia,T/myeloid · myelodysplastic syndrome associated with isolated del(5q) · myelodysplastic syndrome with excess blasts · myelodysplastic/myeloproliferative disease · myelodysplastic/myeloproliferative neoplasm · myelofibrosis · myeloid leukemia · myeloid neoplasm · peripheral T-cell lymphoma, not otherwise specified · premalignant hematological system disease · refractory plasma cell neoplasm · T-cell non-Hodgkin lymphoma · urinary bladder cancer · B-cell childhood acute lymphoblastic leukemia · hematologic disorder · lymphoid leukemia
Investigated by
Genzyme, a Sanofi Company · National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Memorial Sloan Kettering Cancer Center · Nantes University Hospital · St. Jude Children's Research Hospital
+94 more · Dana-Farber Cancer Institute · University of Washington · Fred Hutchinson Cancer Center · GIMEMA Foundation · Masonic Cancer Center, University of Minnesota · Massachusetts General Hospital · Milton S. Hershey Medical Center · Therapeutic Advances in Childhood Leukemia Consortium · Washington University School of Medicine · Baylor Research Institute · Beth Israel Deaconess Medical Center · Bioenvision · City of Hope Medical Center · Hannover Medical School · Hospices Civils de Lyon · Indiana University · New York Medical College · Roswell Park Cancer Institute · SWOG Cancer Research Network · Sanofi · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · UNC Lineberger Comprehensive Cancer Center · University of Chicago · University of Michigan Rogel Cancer Center · Wake Forest University Health Sciences · American Family Children's Hospital · Ann & Robert H Lurie Children's Hospital of Chicago · Assisi Foundation · Assistance Publique - Hôpitaux de Paris · Bayer/Onyx · Betta Pharmaceuticals Co., Ltd. · Brigham and Women's Hospital · Celgene Corporation · Central Hospital, Nancy, France · Centre Hospitalier Universitaire de Besancon · Children's Oncology Group · Cookies for Kids' Cancer · ECOG-ACRIN Cancer Research Group · Eisai Inc. · Ekaterina Laukhtina · Enzon Pharmaceuticals, Inc. · European Organisation for Research and Treatment of Cancer - EORTC · Fondazione Italiana Sindromi Mielodisplastiche-ETS · Gaslini Institute · Groupe Francophone des Myelodysplasies · Institute of Hematology & Blood Diseases Hospital, China · Jazz Pharmaceuticals · Loyola University · Lund University Hospital · Medexus Pharma, Inc. · Medical College of Wisconsin · National Heart, Lung, and Blood Institute (NHLBI) · National University of Singapore · Nationwide Children's Hospital · North American Consortium for Histiocytosis · Northwestern University · Novartis Pharmaceuticals · OHSU Knight Cancer Institute · Ohio State University Comprehensive Cancer Center · Oncology Specialists, S.C. · Otsuka Pharmaceutical Development & Commercialization, Inc. · PETHEMA Foundation · Princess Maxima Center for Pediatric Oncology · Racura Oncology Ltd · Rennes University Hospital · Rush University Medical Center · Saint-Louis Hospital, Paris, France · Sheba Medical Center · Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias · Spectrum Pharmaceuticals, Inc · St. Baldrick's Foundation · Targazyme, Inc. · Technical University Dresden · Texas Oncology Cancer Center · all 100 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) CLOLAR 2008-10-17 – 2022-07-18 fda.gov
Approved EU (EMA) Evoltra 2006-05-29 europa.eu
Approved US (FDA) CLOLAR 2004-12-28 fda.gov

Trials 146 · started per year

today
US approved 2004
EU approved 2006
1
5
4
4
7
13
17
13
16
16
11
7
6
4
3
2
3
1
2
3
1
3
1
1
1
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 134 trials
Phase 1 NCT07156435 Nov 2020 → Dec 2026 expected childhood acute myeloid leukemia Princess Maxima Center for Pediatric Oncology Recruiting No outcome recorded
Phase 1 NCT02211755 Oct 2014 → Aug 2025 lymphoma, myelodysplastic syndrome National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT01629082 Jun 2012 → Oct 2015 acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, neutropenia National Heart, Lung, and Blood Institute (NHLBI) Completed No outcome recorded
Phase 1 NCT01065545 Jun 2011 → ? acute myeloid leukemia Northwestern University Withdrawn No outcome recorded
Phase 1 NCT01169012 Sep 2010 → Apr 2012 acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome UNC Lineberger Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT01196013 Aug 2010 → May 2011 acute lymphoblastic leukemia Genzyme, a Sanofi Company Completed No outcome recorded
Phase 1 NCT01132573 Apr 2010 → Jun 2014 acute biphenotypic leukemia, adult acute lymphoblastic leukemia National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT01090167 Feb 2010 → Apr 2011 acute myeloid leukemia Genzyme, a Sanofi Company Completed No outcome recorded
Phase 1 NCT01041508 Jan 2010 → Aug 2014 acute lymphoblastic leukemia, acute myeloid leukemia Therapeutic Advances in Childhood Leukemia Consortium Completed No outcome recorded
Phase 1 NCT01279096 Jan 2010 → Jun 2012 acute lymphoblastic leukemia University Hospital, Lille Completed No outcome recorded
Phase 1/228 trials
Phase 1/2 NCT07034053 Oct 2023 → Nov 2028 expected urothelial carcinoma Ekaterina Laukhtina Recruiting No outcome recorded
Phase 1/2 NCT02053545 Dec 2013 → May 2017 leukemia, lymphoma, myelodysplastic syndrome Ann & Robert H Lurie Children's Hospital of Chicago Withdrawn No outcome recorded
Phase 1/2 NCT01983761 Nov 2013 → Mar 2014 Hodgkins lymphoma, disease related to transplantation, leukemia, myelodysplastic syndrome +1 Targazyme, Inc. Unknown No outcome recorded
Phase 1/2 NCT01842672 Mar 2013 → Aug 2021 Burkitt lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, diffuse large B-cell lymphoma +1 New York Medical College Completed No outcome recorded
Phase 1/2 NCT01794702 Feb 2013 → Jan 2018 acute leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/2 NCT01534702 Jan 2012 → Apr 2013 acute myeloid leukemia Hannover Medical School Unknown No outcome recorded
Phase 1/2 NCT01289457 Feb 2011 → Jun 2017 leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/2 NCT01422603 Feb 2011 → May 2014 acute myeloid leukemia, myelodysplastic syndrome University Hospital Southampton NHS Foundation Trust Completed No outcome recorded
Phase 1/2 NCT01160354 Aug 2010 → Mar 2016 acute myeloid leukemia M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 1/2 NCT01063257 Apr 2010 → Mar 2014 myelodysplastic syndrome Groupe Francophone des Myelodysplasies Completed No outcome recorded
Phase 275 trials
Phase 2 NCT07022834 Jun 2025 → Jun 2028 expected Langerhans cell histiocytosis West China Second University Hospital Recruiting No outcome recorded
Phase 2 NCT06252870 Jul 2024 → Oct 2027 expected graft versus host disease, hematopoietic and lymphoid cell neoplasm Nantes University Hospital Recruiting No outcome recorded
Phase 2 NCT05917405 Sep 2023 → Sep 2028 expected acute myeloid leukemia Nantes University Hospital Recruiting No outcome recorded
Phase 2 NCT04994808 Aug 2023 → Jan 2026 overdue acute myeloid leukemia, myelodysplastic syndrome Fred Hutchinson Cancer Center Active not recruiting No outcome recorded
Phase 2 NCT04220008 Oct 2021 Burkitt lymphoma, T-cell non-Hodgkin lymphoma, high grade B-cell lymphoma M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 2 NCT04989335 Aug 2021 → Dec 2024 acute myeloid leukemia Sheba Medical Center Unknown No outcome recorded
Phase 2 NCT04761770 Feb 2021 → Feb 2027 expected atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myelomonocytic leukemia, myelodysplastic syndrome Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded
Phase 2 NCT04002115 Jun 2020 → Aug 2022 acute myeloid leukemia Milton S. Hershey Medical Center Terminated No outcome recorded
Phase 2 NCT03615105 Jul 2018 → Mar 2024 Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia Memorial Sloan Kettering Cancer Center Terminated No outcome recorded
Phase 2 NCT03136146 Aug 2017 → Aug 2027 expected B-cell acute lymphoblastic leukemia, Burkitt lymphoma, high-grade B-cell lymphoma double-hit/triple-hit M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT01385891 Aug 2008 → Dec 2009 acute leukemia Gaslini Institute Completed No outcome recorded
Phase 2/3 NCT00454480 Aug 2006 → Aug 2012 leukemia, myelodysplastic syndrome The University of New South Wales Completed No outcome recorded
Phase 35 trials
Phase 3 NCT05477589 Jun 2022 → Dec 2029 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant Vastra Gotaland Region Recruiting No outcome recorded
Phase 3 NCT02883049 Feb 2012 → Dec 2022 B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like, central nervous system leukemia, testicular leukemia National Cancer Institute (NCI) Completed No outcome recorded
Phase 3 NCT01471444 Nov 2011 → Dec 2020 disease related to hematopoietic stem cell transplant, leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 3 NCT02085408 Feb 2011 → Feb 2021 acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +9 ECOG-ACRIN Cancer Research Group Completed No outcome recorded
Phase 3 NCT00317642 Aug 2006 → Jan 2012 acute myeloid leukemia Genzyme, a Sanofi Company Completed No outcome recorded
Phase not applicable2 trials
NCT07644481 Jul 2026 → Dec 2029 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant Institute of Hematology & Blood Diseases Hospital, China Not yet recruiting No outcome recorded
NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
Also used as a comparator or background therapy in 29 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT05569512 Background Oct 2022 → Oct 2023 acute myeloid leukemia, childhood malignant neoplasm Malika Kapadia Terminated No outcome recorded
Phase 1 NCT02083250 Background Mar 2014 → Nov 2021 acute lymphoblastic leukemia, acute myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT01900509 Background Aug 2013 → May 2016 Hodgkins lymphoma, acute leukemia, non-Hodgkin lymphoma St. Jude Children's Research Hospital Completed No outcome recorded
Phase 1 NCT01471067 Background Jul 2012 → Apr 2017 disease related to hematopoietic stem cell transplant, leukemia, lymphoma M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT01031368 Background Dec 2009 → Sep 2012 acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +9 Nohla Therapeutics, Inc. Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT06986382 Background Jul 2025 → Jul 2037 expected Crohn disease Stanford University Not yet recruiting No outcome recorded
Phase 1/2 NCT04727151 Background Apr 2021 → Dec 2023 gastroesophageal cancer Triumvira Immunologics, Inc. Terminated No outcome recorded
Phase 1/2 NCT01629511 Background Nov 2012 → Apr 2018 B-cell chronic lymphocytic leukemia, Richter transformation, disease related to hematopoietic stem cell transplant, prolymphocytic leukemia M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 1/2 NCT01701986 Background Oct 2012 → Jun 2024 B-cell non-Hodgkin lymphoma, Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, disease related to hematopoietic stem cell transplant M.D. Anderson Cancer Center Completed No outcome recorded
Phase 211 trials
Phase 2 NCT07566377 Background Apr 2026 → Apr 2030 expected Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, graft versus host disease +1 Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 2 NCT04644016 Background Nov 2020 → Dec 2026 expected acute myeloid leukemia, bone marrow failure syndrome, hemophagocytic syndrome, inborn errors of metabolism +3 Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 2 NCT03615144 Comparator Jul 2018 → Nov 2020 hematologic disorder Memorial Sloan Kettering Cancer Center Terminated No outcome recorded
Phase 2 NCT03263767 Background Jan 2018 → Oct 2021 graft versus host disease Nantes University Hospital Terminated No outcome recorded
Phase 2 NCT03096782 Background Oct 2017 → Sep 2022 Hodgkins lymphoma, Langerhans cell histiocytosis, acute biphenotypic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +3 M.D. Anderson Cancer Center Completed No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT03117751 Background Mar 2017 → Sep 2026 expected lymphoblastic leukemia, acute, with lymphomatous features St. Jude Children's Research Hospital Active not recruiting No outcome recorded
Phase 2/3 NCT01228331 Comparator Oct 2010 → Dec 2019 leukemia University Medical Center Hamburg-Eppendorf Completed No outcome recorded
Phase 34 trials
Phase 3 NCT02665065 Comparator Jun 2016 → Jun 2022 overdue acute myeloid leukemia Actinium Pharmaceuticals Active not recruiting No outcome recorded
Phase 3 NCT02013167 Comparator Jan 2014 → Dec 2015 B-cell acute lymphoblastic leukemia Amgen Terminated No outcome recorded
Phase 3 NCT00703820 Comparator Aug 2008 → Mar 2017 acute myeloid leukemia St. Jude Children's Research Hospital Completed No outcome recorded
Phase 3 NCT00549848 Background Oct 2007 → Sep 2020 acute lymphoblastic leukemia St. Jude Children's Research Hospital Completed No outcome recorded
Phase not applicable2 trials
NCT01626092 Background Jul 2012 → Nov 2013 lysosomal storage disease, peroxisomal disease Masonic Cancer Center, University of Minnesota Completed No outcome recorded
NCT00187096 Background Sep 2005 → Feb 2012 acute myeloid leukemia St. Jude Children's Research Hospital Completed No outcome recorded

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 178 sources stand behind the page.

FieldValueCited text
Known as Clofarabine Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days.” NCT02013167
174

Clofarabine is a second generation nucleoside analog FDA approved for the treatment of relapsed and refractory pediatric ALL” NCT00983528

Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)” NCT02053545

“Chemotherapies: busulfan, fludarabine, melphalan, cyclophosphamide, thiotepa, clofarabineNCT04761770

Clofarabine is designed to interfere with the growth and development of cancer cells.” NCT01794702

Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion.” NCT00626626

Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6” NCT00932412

“Cladribine, Clofarabine, Crizotinib” NCT02788201

“Cladribine Clofarabine Crizotinib” NCT02551718

clofarabine and cyclophosphamide” NCT04727151

ClofarabineNCT02665065

NCT00903760

NCT02211755

NCT07566377

NCT00839982

NCT00556452

NCT04220008

NCT00708721

NCT00727766

NCT00857389

NCT01596699

NCT01119066

NCT01188174

NCT00383448

NCT00065143

NCT02135874

NCT01025778

NCT01700946

NCT01457885

NCT02085408

NCT01041508

NCT00412243

NCT01842672

NCT07644481

NCT00503880

NCT02727803

NCT01471444

NCT00973752

NCT01279096

NCT02441803

NCT00882076

NCT00638820

NCT00724009

NCT01626092

NCT01090167

NCT07156435

NCT00617929

NCT00337168

NCT00549848

NCT01471067

NCT00531232

NCT00991133

NCT01295307

NCT02349178

NCT00044889

NCT00990249

NCT01885689

NCT00700011

NCT01065545

NCT01228331

NCT01462253

NCT01621477

NCT04644016

NCT05569512

NCT00908167

NCT00498316

NCT01983761

NCT00098033

NCT00593645

NCT02518750

NCT03615144

NCT04994808

NCT04002115

NCT00081822

NCT00416351

NCT00067028

NCT00945815

NCT05477589

NCT00156013

NCT03117751

NCT05917405

NCT00462787

NCT01101880

NCT00295841

NCT01796405

NCT01422603

NCT01025154

NCT00187096

NCT00602225

NCT00641030

NCT01534702

NCT00800566

NCT01451515

NCT02686593

NCT01158885

NCT00775593

NCT04989335

NCT00338494

NCT00334074

NCT00814164

NCT01701986

NCT01629511

NCT00943592

NCT00373529

NCT01289457

NCT03096782

NCT00691652

NCT00088218

NCT00241371

NCT00372619

NCT01677949

NCT02544789

NCT01196013

NCT01629082

NCT00863148

NCT03136146

NCT00081887

NCT00852709

NCT03615105

NCT00454480

NCT00644189

NCT07034053

NCT00469014

NCT00125827

NCT02083250

NCT00299156

NCT00028418

NCT00697684

NCT00042354

NCT00422032

NCT01132573

NCT01423175

NCT00703820

NCT06252870

NCT00477542

NCT01160354

NCT00750334

NCT00824135

NCT01900509

NCT00042341

NCT01500161

NCT01063257

NCT01643668

NCT00863434

NCT00939653

NCT01656031

NCT00423514

NCT00924443

NCT01302106

NCT00852163

NCT00315705

NCT02425904

NCT03263767

NCT02883049

NCT00930098

NCT00125840

NCT00529360

NCT01252667

NCT00293410

NCT00838240

NCT00201669

NCT06986382

NCT00778375

NCT01385891

NCT01003678

NCT00697671

NCT07022834

NCT01193400

NCT01169012

NCT00577694

NCT01031368

NCT01444742

NCT01960387

NCT00317642

NCT00477945

Known as Clo “Patients were randomly assigned to receive either clofarabine (Clo) 40 mg/m(2) or a placebo followed by Ara-C 1 g/m(2) for five consecutive days.” PMID 22585697 May 2012
2

“The authors of this report investigated the safety and efficacy of clofarabine (CLO) in these patients.” PMID 21425150 Nov 2010

“Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes” NCT04989335

Known as Clofarabina ChEMBL registry synonym — accepted as the source's own label CHEMBL1750
Known as Clofarabine (2-chloro-9-[2-deoxy-2-fluoro-D-arabinofuranosyl]adenine; Cl-F-ara A; CAFdA Clofarabine (2-chloro-9-[2-deoxy-2-fluoro-D-arabinofuranosyl]adenine; Cl-F-ara A; CAFdANCT00708721
Known as Clolar ChEMBL registry synonym — accepted as the source's own label CHEMBL1750
Known as Clolar (intravenous clofarabine) Clolar (intravenous clofarabine)NCT01169012
Known as Evoltra ChEMBL registry synonym — accepted as the source's own label CHEMBL1750
Known as Ivozall ChEMBL registry synonym — accepted as the source's own label CHEMBL1750
Known as NSC-759857 ChEMBL registry synonym — accepted as the source's own label CHEMBL1750
Known as tradename EU = Evoltra tradename EU = EvoltraNCT00924443
Known as tradename US = Clolar tradename US = ClolarNCT00924443
Known as ◦Drug: Clofarabine ◦Drug: ClofarabineNCT01983761
Action Inhibit “Mechanisms of action include inhibition of DNA synthesis, inhibition of DNA polymerases, and potent inhibition of ribonucleotide reductase (RNR) resulting in depletion of...” NCT00065143
Modality Other / unclassified “synthesized hybrid nucleoside analog” NCT00028418
Route Intravenous “clofarabine (IV formulation)” NCT00042341